Good morning, everyone. The world is watching China, the new coronavirus, and the outbreak’s spread. STAT is covering those developments while continuing to monitor news from pharma — which sometimes intersect. Here are some items to start your day.
Even in a primary dominated by broader health care issues, insulin has emerged as particularly alluring campaign fodder for Democrats, STAT reports from Iowa. Unlike more perplexing topics like health insurance reform or the cost of drug research, candidates have a plain and simple rallying cry for insulin: That it’s corporate profiteering. “Everything is coming together,” said Lija Greenseid, a Minnesota-based advocate working to push insulin into the political mainstream. “We’ve finally caught the attention of people in power.”
About the Author Reprints
